Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 184Carcinoma, Non-Small-Cell Lung 142Multiple Myeloma 119Prostatic Neoplasms 116Colorectal Neoplasms 75Leukemia, Myeloid, Acute 74Neoplasms 73Melanoma 71Squamous Cell Carcinoma of Head and Neck 65Lymphoma 64Lung Neoplasms 64Neoplasm Metastasis 63Pancreatic Neoplasms 55Ovarian Neoplasms 49Sarcoma 45Carcinoma, Renal Cell 45Triple Negative Breast Neoplasms 42Urinary Bladder Neoplasms 41Leukemia, Lymphocytic, Chronic, B-Cell 41Glioblastoma 41Carcinoma, Hepatocellular 41Recurrence 40Head and Neck Neoplasms 37Lymphoma, Large B-Cell, Diffuse 35Brain Neoplasms 35Myelodysplastic Syndromes 34Hematologic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Lymphoma, Non-Hodgkin 33Lymphoma, Mantle-Cell 32

Interventions

Paclitaxel 2Cisplatin 2Carboplatin 2cemiplimab 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Resectable Non-small Cell Lung Cancer × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

NCT05247684 2026-03-05

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Akeso

Phase 2 Active not recruiting
90 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡